NDA 215428 · Almatica
Citalopram Hydrobromide
Citalopram Hydrobromide · Oral
Last checked: Nov 19, 2026Latest source record: Aug 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Jan 31, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
220
32 Phase 3, 6 recruiting
FAERS reports
107,749
88,370 serious, 17,192 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )]. Citalopram Capsules is not approved for use in pediatric patients [see Use in Specific Populations ( 8.4 )]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). Citalopram Capsules is not approved for use in pediatric patients ( 8.4 ).
What it is approved for
From the label in effect Oct 7, 2025.
Citalopram Capsules are indicated for the treatment of Major Depressive Disorder (MDD) in adults [see Clinical Studies ( 14 )] . Citalopram Capsules is a selective serotonin reuptake inhibitor (SSRI) indicated for treatment of Major Depressive Disorder (MDD) in adults. ( 1 )
Mechanism: The mechanism of action of citalopram as an antidepressant is unclear, but is presumed to be related to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 31, 2022 Original approval · Type 2 - New Active Ingredient and Type 3 - New Dosage Form LetterLabelReview
1 products under this application
- CITALOPRAM HYDROBROMIDE · CITALOPRAM HYDROBROMIDE EQ 30MG BASE · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Citalopram Hydrobromide" as an intervention, any sponsor and status, largest first.
- Sequenced Treatment Alternatives to Relieve Depression (STAR*D)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00021528 · 4,000 participants · Start Jul 2001
Drug: citalopram; BuproprionSR and 8 more · For: Depression
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Chula Vista, California · 41 sites in all
Peking UniversityAcademic, hospital or other
NCT02023567 · 2,400 participants (planned) · Start Nov 2013 · Primary completion Dec 2016
Drug: SSRIs · For: Depressive Disorder, Major
Sites: Beijing, China; Shijiazhuang, China; Dalian, China · 9 sites in all
Ege UniversityAcademic, hospital or other
NCT04776226 · 1,230 participants · Start Feb 11, 2017 · Primary completion Mar 10, 2018
Drug: Citalopram · For: Stroke Recurrence; Cardiovascular Events; Depression
Sites: Izmir, Turkey (Türkiye)
- Safety and Efficacy of Vilazodone in Major Depressive DisorderPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT01473381 · 1,162 participants · Start Dec 2011 · Primary completion Jun 2013
Drug: Vilazodone; Placebo to citalopram and 2 more · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Dothan, Alabama; Scottsdale, Arizona · 54 sites in all
- A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT03538691 · 1,149 participants · Start Jul 13, 2018 · Primary completion Jul 8, 2022
Drug: Brexpiprazole; Antidepressant therapy · For: Major Depressive Disorder
Sites: Los Angeles, California
- Algorithm Guided Treatment Strategies for Major Depressive DisorderPivotal-lookingStatus unknown
Shanghai Mental Health CenterAcademic, hospital or other
NCT01764867 · 1,080 participants (planned) · Start Jun 2012 · Primary completion Oct 2014
Drug: Escitalopram; Mirtazapine and 11 more · For: Major Depressive Disorder
Sites: Shanghai, China
- Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)Pivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT01715805 · 1,022 participants · Start Nov 15, 2012 · Primary completion Jun 24, 2016
Drug: Cariprazine; Placebo and 1 more · For: Major Depressive Disorder
Sites: Tucson, Arizona; Little Rock, Arkansas; Cerritos, California · 85 sites in all
Samsung Medical CenterAcademic, hospital or other
NCT00817011 · 1,000 participants (planned) · Start Apr 2006 · Primary completion Dec 2016
Drug: SSRI treated group; non-SSRI treated group · For: Depression; Antidepressant Drug Adverse Reaction
Sites: Kangnam, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue7,087
- nausea6,075
- drug ineffective5,636
- headache5,236
- toxicity to various agents5,192
- diarrhoea4,873
- fall4,497
- pain4,483
- dizziness4,467
- off label use4,427
- completed suicide4,228
- dyspnoea4,187
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 803 |
| 2005 | 1,012 |
| 2006 | 1,091 |
| 2007 | 1,414 |
| 2008 | 2,043 |
| 2009 | 2,348 |
| 2010 | 2,849 |
| 2011 | 3,921 |
| 2012 | 4,855 |
| 2013 | 4,751 |
| 2014 | 5,906 |
| 2015 | 7,383 |
| 2016 | 7,684 |
| 2017 | 7,125 |
| 2018 | 8,132 |
| 2019 | 8,606 |
| 2020 | 7,289 |
| 2021 | 6,249 |
| 2022 | 5,329 |
| 2023 | 5,387 |
| 2024 | 5,021 |
| 2025 | 5,202 |
| 2026 | 3,346 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of Facial Botulinum Toxin A Injections in Alleviating Neuropsychiatric Symptoms in Parkinson's Disease Patients: An Open-Label, Nonrandomized Controlled Trial.
Li H, Wei M, Zhu X, et al. · Brain Behav 2025 · Controlled Clinical Trial
- Salvage use of citalopram for treatment of fluoxetine-resistant premature ejaculation in recently married men: a prospective clinical trial.
Dadfar MR, Baghinia MR · Urol J 2010 · Clinical Trial
- A randomized, placebo-controlled trial of citalopram for the prevention of major depression during treatment for head and neck cancer.
Lydiatt WM, Denman D, McNeilly DP, et al. · Arch Otolaryngol Head Neck Surg 2008 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial.
King BH, Dukes K, Donnelly CL, et al. · JAMA Pediatr 2013 · Multicenter Study, Randomized Controlled Trial
- Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease.
Rosenheck RA, Leslie DL, Sindelar JL, et al. · Arch Gen Psychiatry 2007 · Multicenter Study, Randomized Controlled Trial
- Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism.
King BH, Hollander E, Sikich L, et al. · Arch Gen Psychiatry 2009 · Multicenter Study, Randomized Controlled Trial
Sponsor: Almatica
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.